Clarity Pharmaceuticals Ltd.(AU:CU6)
A$1.82-0.23 (-11.46%)
AU:CU6
Clarity Pharmaceuticals Ltd. stock drug pipeline
A$1.82
At close:-0.23 (-11.46%)
Want to see AU:CU6 full AI Analyst Report?
Clarity Pharmaceuticals Ltd. (CU6) Drug Pipeline
305 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 64Cu-Sar-Bispsma | Prostate Cancer, Prostate Cancer Patients With Detectable Psa Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated By Radiotherapy, Cryotherapy | Phase III | Recruiting | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Apr 29, 2025 | ― |
| 64Cu-Sar-Bispsma | Prostate Cancer, Prostatic Neoplasms | Phase III | Recruiting | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Sep 21, 2023 | ― |
| 64Cu-Sar-Bbn, 67Cu-Sar-Bbn | Prostatic Neoplasms, Castration-Resistant | phase1AndPhase2 | Terminated | 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) | Nov 21, 2022 | ― |
| 64Cu-Sar-Bbn | Biochemical Recurrence Of Malignant Neoplasm Of Prostate | Phase II | Completed | 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) | Jun 02, 2022 | ― |
| 64Cu-Sar-Bispsma, 67Cu-Sar-Bispsma | Prostatic Neoplasms, Castration-Resistant | phase1AndPhase2 | Recruiting | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Apr 15, 2021 | ― |
| 64Cu-Sartate | Neuroendocrine Tumors | Phase II | Completed | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | Jun 11, 2020 | ― |
| 64Cu-Sartate, 67Cu-Sartate | Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma | phase1AndPhase2 | Terminated | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | Jul 14, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 64Cu-Sar-Bispsma | Phase III | Prostate Cancer, Prostate Cancer Patients With Detectable Psa Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated By Radiotherapy, Cryotherapy | Recruiting | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Apr 29, 2025 | ― |
| 64Cu-Sar-Bispsma | Phase III | Prostate Cancer, Prostatic Neoplasms | Recruiting | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Sep 21, 2023 | ― |
| 64Cu-Sar-Bbn, 67Cu-Sar-Bbn | phase1AndPhase2 | Prostatic Neoplasms, Castration-Resistant | Terminated | 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) | Nov 21, 2022 | ― |
| 64Cu-Sar-Bbn | Phase II | Biochemical Recurrence Of Malignant Neoplasm Of Prostate | Completed | 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) | Jun 02, 2022 | ― |
| 64Cu-Sar-Bispsma, 67Cu-Sar-Bispsma | phase1AndPhase2 | Prostatic Neoplasms, Castration-Resistant | Recruiting | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Apr 15, 2021 | ― |
| 64Cu-Sartate | Phase II | Neuroendocrine Tumors | Completed | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | Jun 11, 2020 | ― |
| 64Cu-Sartate, 67Cu-Sartate | phase1AndPhase2 | Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma | Terminated | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | Jul 14, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Clarity Pharmaceuticals Ltd. (AU:CU6) have in its pipeline
Clarity Pharmaceuticals Ltd. AU:CU6 is currently developing the following drugs: 64Cu-Sar-Bispsma, 64Cu-Sar-Bbn, 67Cu-Sar-Bbn, 64Cu-Sar-Bbn, 64Cu-Sar-Bispsma, 67Cu-Sar-Bispsma, 64Cu-Sartate, 64Cu-Sartate, 67Cu-Sartate. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

